Research chemicalResearch chemicalPsychedelicLysergamide

ETH-LAD

Also known as 6-ethyl-6-nor-LSD

Written by enwyReviewed 4 Aug 20262 sources0 comments

ETH-LAD (6-ethyl-6-nor-LSD) is a lysergamide analogue of LSD in which the N6 methyl group is replaced by ethyl. It is somewhat more potent than LSD and reported to be more visual, with a notable body load and vasoconstriction. Active doses are in the microgram range. Human data are almost entirely anecdotal.

01 Overview

ETH-LAD is a semi-synthetic lysergamide first described by Shulgin and a 5-HT2A agonist. Replacing the N6 methyl of LSD with an ethyl group modestly increases potency and, by user accounts, shifts the experience toward stronger visuals and a heavier body load. It is active in micrograms and usually taken orally or sublingually.

Reports frequently mention pronounced physical effects, including vasoconstriction and body tension, sometimes more than with LSD at equivalent intensity. As a lysergamide research chemical, potency varies between batches and blotter dosing is imprecise, making titration difficult. Formal human pharmacology is lacking.

02 Mechanism

Lysergamide agonist at serotonin 5-HT2A (and other serotonin) receptors; N6-ethyl substitution modestly increases potency relative to LSD.

03 Dosing

Tier	Dose	Route	Notes
Threshold	20–40 mcg	Oral	Active in micrograms; slightly more potent than LSD.
Common	50–100 mcg	Sublingual	Reported more visual than LSD; individual sensitivity varies.
Strong	100–200 mcg	Oral	Strong visuals with pronounced body load and vasoconstriction.

04 Effects

Effect	Magnitude	Evidence
Strong visual psychedeliaReported as more visually intense than LSD at comparable doses.	strong	Anecdotal
Mood and cognitive alterationEmotional and introspective effects typical of lysergamides.		Anecdotal
Body loadNoticeable physical tension and stimulation reported.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Vasoconstriction and body tensionPeripheral vasoconstriction and muscle tension reported, sometimes more than with LSD.	Moderate	Common	Anecdotal
Anxiety and difficult experiencesOverwhelming states can occur, especially with imprecise dosing.	Moderate	Common	Anecdotal

06 Legal status

United Kingdom

Class A

Covered as an LSD-related lysergamide. · as of Jan 2026

United States

Schedule I

May be treated as an LSD analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Shulgin A, Shulgin A. TiHKAL: The ContinuationTransform Press, 1997

ETH-LAD entryPsychonautWiki

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.